Nano Bugle

A window into applied science supported by INL

NanoEmulsion That Kills Highly Resistant Bacteria

One of the biggest problems for people with cystic fibrosis is the infection in the respiratory system. This infection is what causes the most deaths among these patients.

Conventional treatments, whether taken orally or intravenous, are not usually effective in many cases owing to the fact of that certain bacterial species are resistant to all known antibiotics. These bacteria cause lung failure in cystic fibrosis patients. The problem with the actual treatments is that, although they work as frontline therapy, systemic drugs are not enough to finish with bacteria or penetrate thick sputum and bacterial biofilms that coat the bacteria, because they do not reach respiratory system with an adequate amount of strength.

Scientists at NanoBio Corp., a spinout from the University of Michigan, and the University of Michigan performed laboratory tests over 150 multi drug resistant bacteria and pan resistant (completely multi drug resistant) bacteria obtained from cystic fibrosis patient’s lungs to evaluate the novel topical nanoemulsion effectiveness. According to the tests, this nanoemulsion kills highly resistant strains of bacteria, showing bacterial activity in the presence of cystic fibrosis sputum and into the protective coats that surrounds the bacterial colony so-called bacterial biofilms, which put a stop to the drugs.

One of the reasons of the efficiency of this nanoemulsion is the possibility of nebulize it. This will place it straight into the lung in order to treat the antibiotic resistant infections. This way, it is possible to get high local concentrations that would be unachievable with an oral systemic drug, as it would cause systemic toxicity.

The Company considers that it is possible supplying for sure to the lung concentrations of this nanoemulsion and that it will be effective to kill bacteria, based on preclinical and clinical security data from NanoBio’s topical anti-infective products. The Firm also notes that the benefit from this treatment will contribute to reduce the bacterial colony to levels that the body can handle effectively so that the patient will suffer less acute episodes and fewer hospitalizations.

NanoBio Corp. expects to test in patients with cystic fibrosis in 2010.


February 10, 2009 - Posted by | Nanomedicine

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: